Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone undecanoate + dutasteride
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Testosterone undecanoate + dutasteride is a combination therapy consisting of an androgen (testosterone undecanoate) and a dual 5α-reductase inhibitor (dutasteride). Testosterone undecanoate is an ester prodrug of testosterone used for testosterone replacement therapy in adult males with primary or hypogonadotropic hypogonadism. It restores physiological levels of testosterone to treat symptoms related to deficiency such as reduced libido and muscle mass[4][5][7]. Dutasteride inhibits both type I and II 5α-reductase enzymes that convert testosterone into dihydrotestosterone (DHT), thereby reducing DHT-mediated effects like prostate enlargement[1]. The combination may be used experimentally or off-label to optimize androgen replacement while minimizing DHT-related side effects such as acne or benign prostatic hyperplasia. Dutasteride can also increase the oral bioavailability of testosterone by suppressing its conversion to DHT[3][5].
- Brand names
- Andriol
- Other names
- testosterone undecanoate + dutasterideTU + dutasteride
02
Targets
SRD5A1 (Steroid 5-alpha-reductase type 1)SRD5A2 (Steroid 5-alpha-reductase type II)AR (Adrenergic receptors)
Beyond the preview
Go deeper on testosterone undecanoate + dutasteride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone undecanoate + dutasteride.